Researchers suggest short transition period between RRMS therapies
A team led by researchers at the University Hospital Basel in Switzerland say they have found a short period of eight to 12 weeks is the optimal timing to be considered when patients with relapsing-remitting multiple sclerosis (RRMS) are switched from Tysabri (natalizumab) to Gilenya (fingolimod) therapy.... Read More - http://www.ms-uk.org/gilenya
Researchers suggest short transition period....
Researchers suggest short transition period....
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post